TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17023713
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg DHA + 150 mg eicosapentaenoic acid, 400 microg 5‐methyl‐tetrahydrofolic acid
Study: 19492924
Drug: Outpatient cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient cervical ripening by prostaglandins or other cervical ripening agents
Study: 10211515
Drug: Medical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical bowel confinement (clear liquid diet with loperamide 4 mg three times per day and codeine phosphate 30 mg four times per day until the third postoperative day)
Study: 113806
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia with naloxone
Study: 113806
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia with placebo
Study: 6357258
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penbutolol and frusemide
Study: 31340789
Drug: Probiotic strains
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic strains Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, administered orally (one capsule daily) until negative HR-HPV testing.
Study: 22974092
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in tumor marker levels during treatment
Study: 21990564
Drug: Intra-arterial thrombolysis
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolysis (IAT) with up to 0.9 mg/kg alteplase over 60 min
Study: 21990564
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) with alteplase according to European labeling
Study: 8485825
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor treatment (specific drug not mentioned)
Study: 2866047
Drug: Metoprolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (150 mg/day)
Study: 2006616
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg/day)
Study: 19387386
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g per day, 4 doses of 5 g per day)
Study: 11803729
Drug: Amisulpride (100-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (100-1200 mg/day)
Study: 9617983
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (220 mg every 8 hours)
Study: 9617983
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (300 mg every 12 hours) with acetaminophen
Study: 2532921
Drug: Frusemide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (30 mg)
Study: 2532921
Drug: Frusemide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (30 mg) with ramipril (5 mg) pretreatment
Study: 788889
Drug: Cyclophosphamide, 10
Normalized name: Cyclophosphamide, 100 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, 10 mg/kg/day orally for 7-10 days every 28 days for 1 year
Study: 22193786
Drug: Best practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices model within the juvenile court system for early mental health intervention, including screening with the Youth Outcome Questionnaire and treatment involving psychiatric care and in-home behavioral intervention.
Study: 11568790
Drug: Ceftriaxone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 125 mg intramuscularly
Study: 27236082
Drug: Cross-sex hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sex hormone treatment (4 weeks and 4 months duration) in MtF and FtM transgender individuals
Study: 23672386
Drug: 3.5 mL
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mL menthol gel
Study: 23672386
Drug: 3.5 mL
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mL of menthol gel and 0.5 kg of crushed ice
Study: 10233876
Drug: PIXY321 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIXY321 administered subcutaneously in divided doses of 135, 250, 500, 750, and 1,000 micrograms/m2/d during cycles 2 and later
Study: 10233876
Drug: PIXY321 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIXY321 administered during cycles A-2 and B-1
Study: 7982342
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment with bronchodilators and anti-inflammatory agents
Study: 7982342
Drug: Adjunctive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive and nonconventional therapy
Study: 31905607
Drug: 40-g protein
Normalized name: soy protein isolate 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g protein drink
Study: 25322870
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADLs) and cognitive assessment
Study: 17229660
Drug: 40% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% of total daily insulin requirement
Study: 17229660
Drug: 60% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% of total daily insulin requirement
Study: 17229660
Drug: 80% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% of total daily insulin requirement
Study: 3234467
Drug: Simvastatin 20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20‐40 mg/day
Study: 8560901
Drug: Bezafibrate 600
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 600 mg/day
Study: 16861095
Drug: Levetiracetam 1,500
Normalized name: levetiracetam 1,500 mg ORAL TABLET, EXTENDED RELEASE 24 HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1,500 mg IV infusion
Study: 16861095
Drug: Levetiracetam 500
Normalized name: levetiracetam 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 500 mg oral tablets
Study: 16861095
Drug: Levetiracetam 1,500
Normalized name: levetiracetam 1,500 mg ORAL TABLET, EXTENDED RELEASE 24 HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1,500 mg IV infusion (multiple doses)
Study: 28929521
Drug: Placebo (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple doses)
Study: 12646326
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (tapered dosing regimen)
Study: 24925584
Drug: Novolin® 30R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novolin® 30R (initial dose 0.5 IU/kg)
Study: 12534411
Drug: Rabeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (10 mg b.d.) + Amoxicillin (750 mg b.d.) + Clarithromycin (400 mg b.d.)
Study: 12534411
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg b.d.) + Amoxicillin (750 mg b.d.) + Clarithromycin (400 mg b.d.)
Study: 10497402
Drug: Step‐by‐step pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐by‐step pharmacologic therapy including bronchodilators (beta 2‐agonists, anticholinergic agents), theophylline, and oral corticosteroids
Study: 1849810
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg single oral dose
Study: 1849810
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 to 40 mg twice daily for 4 weeks
Study: 7000631
Drug: PGE2 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 (1 mg four times daily) with ASA (600 mg four times daily)
Study: 31152605
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 mg/kg every 2 weeks)
Study: 28067718
Drug: Safety assessment
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety assessment of both vaccines
Study: 9207314
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine combination
Study: 9207314
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus cisplatin-based chemotherapy
Study: 2442788
Drug: Reserpine 5
Normalized name: hydralazine HCl/reserpine 50-0.2MG ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine 5 mg IM b.i.d. over 2 days (placebo-controlled, double-blind trial)
Study: 2442788
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) treatment
Study: 2442788
Drug: Reserpine augmentation
Normalized name: Reserpine
DrugBank: Reserpine (DB00206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reserpine augmentation
Study: 29486353
Drug: Antibiotic +
Normalized name: Antibiotic + Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic + indocyanine green + 810 nm wavelength diode laser (antimicrobial photodynamic therapy group)
Study: 29486353
Drug: Antibiotic alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic alone (control group)
Study: 26836801
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment daily for two weeks
Study: 25260838
Drug: Pasireotide 40
Normalized name: pasireotide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 40 mg
Study: 27280398
Drug: Pasireotide 60
Normalized name: pasireotide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 60 mg
Study: 23581697
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate 240 mg/d
Study: 23581697
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate 80 mg/d, 160 mg/d, 240 mg/d
Study: 18972728
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy group (active exercise after passive exercise)
Study: 30938762
Drug: Comparator (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (placebo or active comparator: sitagliptin 100 mg, exenatide extended release 2.0 mg)
Study: 28424190
Drug: Inulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (30 g/d)
Study: 28424190
Drug: Propionate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionate (6 g/d)
Study: 28424190
Drug: Cellulose (30
Normalized name: hydroxyethyl cellulose (3000 CPS at 1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (30 g/d)
Study: 25154757
Drug: Dipyrone (575
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (575 mg, three times a day for 72 hr)
Study: 25154757
Drug: Acetaminophen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500 mg, three times a day for 72 hr)
Study: 24107481
Drug: Docetaxel 40
Normalized name: docetaxel 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 40 mg/m² and cisplatin 40 mg/m² biweekly on days 1 and 15 every 4 weeks
Study: 21375777
Drug: Single-dose AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose AmBisome® (7.5 mg/kg, escalating to 10, 12.5, and 15 mg/kg if ineffective)
Study: 21375777
Drug: Multi-dose AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose AmBisome® (3 mg/kg/day on days 1-5, 14, and 21; total dose 21 mg/kg)
Study: 21375777
Drug: Single-dose AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose AmBisome®
Study: 21375777
Drug: Multi-dose AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose AmBisome®
Study: 19533313
Drug: Active allergen
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active allergen immunotherapy (IT) with single insect extract (cockroach, housefly, or mosquito) and mixed allergen IT (two or three insect extracts)
Study: 12538427
Drug: L‐NMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA
Study: 10648310
Drug: Oral ketamine/midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine/midazolam
Study: 10648310
Drug: Intramuscular meperidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine, promethazine, and chlorpromazine (DPT)
Study: 8862501
Drug: Bromocriptine (BRC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (BRC, 2.5 mg po)
Study: 1738963
Drug: One-dose regimen
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose regimen of cefuroxime
Study: 6469757
Drug: Misonidazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole treatment
Study: 20551634
Drug: Intravaginal pentamycin
Normalized name: Benzamycin
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal pentamycin 3, 10, 30, 60 or 100 mg
Study: 20551634
Drug: Intravaginal pentamycin
Normalized name: Benzamycin
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal pentamycin 60 mg
Study: 12394817
Drug: PnCV reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PnCV reconstituted in TETRAMUNE as a single injection in the right thigh (combined)
Study: 25800457
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate once‐monthly injectable antipsychotic (PP1M)
Study: 25800457
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate adjunctive therapy (PP1M)
Study: 30323359
Drug: 24IU intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24IU intranasal oxytocin
Study: 22889586
Drug: 48IU intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48IU intranasal oxytocin
Study: 1955002
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP)
Study: 2268518
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate tablets at a dose of 1 g twice daily
Study: 26927445
Drug: Sodium-glucose co-transporter-2
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose co-transporter-2 inhibitors
Study: 20576732
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg once daily (Tio)
Study: 16814402
Drug: Pain relievers
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain relievers (opioids, paracetamol, diclofenac)
Study: 8706194
Drug: Sublingual triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual triazolam 0.2 mg (T)
Study: 8706194
Drug: Peroral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral diazepam 10 mg (D)
Study: 2082487
Drug: Dipyridamole 100
Normalized name: dipyridamole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 100 mg q.i.d. starting 2 days before surgery, followed by aspirin 325 mg t.i.d. plus dipyridamole 75 mg t.i.d. 7 hours after surgery
Study: 2082487
Drug: Antiplatelet regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet regimen (dipyridamole and aspirin)
Study: 346168
Drug: Base alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base alone applied four times daily for one week
Study: 27838323
Drug: Grass SLIT-tablet
Normalized name: Timothy grass pollen extract Sublingual Tablet [Grastek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass SLIT-tablet (MK-7243; ≤2800 bioequivalent allergen units/75,000 SQ-T dose)
Study: 27838323
Drug: Short ragweed
Normalized name: weed pollen-short ragweed
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short ragweed SLIT-tablet (MK-3641; ≤12 Amb a 1-U)
Study: 27838323
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite SLIT-tablet (MK-8237; ≤12 SQ-HDM)
Study: 27838323
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for all SLIT-tablet trials)
Study: 31613323
Drug: Ongoing anticholinergic
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing anticholinergic medication
Study: 27452270
Drug: OFD +
Normalized name: OFDZ
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFD + PRF + 1.2% RSV gel
Study: 23113643
Drug: fermented bilberry
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fermented bilberry extract (400 mg/day)
Study: 9249109
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl infusion (Group III)
Study: 9249109
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (Group II)
Study: 27451347
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids and severity-specific inhaled bronchodilator therapy
Study: 15923168
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for multiple myeloma
Study: 8522640
Drug: Ro 41-3696
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 41-3696 at doses of 10 mg and 30 mg
Study: 17522399
Drug: Advanced life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced life support (ALS) treatment, including endotracheal intubation and intravenous drugs, administered to 56.6% of patients during the second phase.
Study: 17522399
Drug: Intravenous drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drugs administered to 15.0% of patients during the second phase.
Study: 17522399
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of nebulized salbutamol and sublingual nitroglycerin increased during the second phase.
Study: 14742379
Drug: memantine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine (30 mg/d)
Study: 11167376
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with polyurethane-coated cotton encasings for bedding
Study: 9459625
Drug: Cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine treatment (interferon-alpha or interferon-beta, either alone or in combination with interleukin-2 or antineoplastic agents)
Study: 7949265
Drug: CDCA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (15 mg/kg/day for 15-20 days)
Study: 2851180
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/m2 on day 1)
Study: 7911677
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and postoperative chemotherapy (5-drug-combination + tamoxifen)
Study: 31373827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment + observation)
Study: 22673924
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg daily)
Study: 22673924
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 U daily)
Study: 28624580
Drug: PPI (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (pantoprazole 40 mg/day)
Study: 15206014
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a second opioid at low doses (initial equivalent dosage of 20% of previous therapy)
Study: 15206014
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a second opioid at low doses
Study: 2512104
Drug: Phenobarbital administered
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital administered by primary health care workers trained by a three-day course in community 'A'
Study: 2512104
Drug: Phenobarbital administered
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital administered by neurologists in community 'B'
Study: 28685353
Drug: Peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon beta-1a 125 mcg
Study: 25381447
Drug: Monolingual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monolingual treatment
Study: 16019861
Drug: Local hyperthermia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local hyperthermia treatment (Group A)
Study: 10522998
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg triptorelin im every 4 weeks for 2 years (n = 20)
Study: 7851581
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 10)
Study: 7295489
Drug: Diacetolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacetolol 200 mg
Study: 26746199
Drug: Home-care F(−)
Normalized name: Gelato Home-Care 1.1 % Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-care F(−) treatment (FD) - 1,100 ppm F(−) dentifrice, 2x1 min/day